Clinical Trials Browser

Suspended × Interventional × 1 year × Clear all

NCT03494569 2026-03-18

Total Marrow and Lymphoid Irradiation, Fludarabine, and Melphalan Before Donor Stem Cell Transplant in Treating Participants With High-Risk Acute Leukemia or Myelodysplastic Syndrome

Phase 1 Suspended

LymphoidMyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Neoplasm, Residual, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04301076 2026-03-18

Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATLL)

Phase 1 Suspended

LymphoidOther hematologic neoplasm

Lymphoma, HTLV-I Infections, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT04616560 2026-03-18

Trastuzumab Deruxtecan for the Treatment of HER2+ Newly Diagnosed or Recurrent Osteosarcoma

Phase 2 Suspended

Osteosarcoma

NCT04799275 2026-03-18

Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma

Phase 2/3 Suspended

Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone

NCT04840589 2026-03-18

Testing the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid Tumors

Phase 1 Suspended

Neoplasm Metastasis, Ovarian Neoplasms

NCT04929041 2026-03-18

Testing the Addition of Radiation Therapy to the Usual Treatment (Immunotherapy With or Without Chemotherapy) for Advanced Stage Non-small Cell Lung Cancer Patients Who Are PD-L1 Negative

Phase 2/3 Suspended

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05223036 2026-03-18

Testing Obeticholic Acid for Familial Adenomatous Polyposis

Phase 2 Suspended

Gastrointestinal

Attenuated familial adenomatous polyposis, Duodenal Neoplasms, Adenomatous Polyposis Coli, Colorectal Neoplasms

NCT05372614 2026-03-18

Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene

Phase 1 Suspended

Neoplasm Metastasis

NCT05432804 2026-03-18

Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment

Phase 1/2 Suspended

Glioblastoma

NCT05554380 2026-03-18

Study of Chemotherapy Plus Ipatasertib for People With Solid Tumors With PTEN/AKT Mutations, A ComboMATCH Treatment Trial

Phase 2 Suspended

Neoplasm Metastasis

NCT05642195 2026-03-18

Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer

Phase 1/2 Suspended

Carcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasm, Residual

NCT06015880 2026-03-18

Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Phase 1 Suspended

Lymphoma, Large B-Cell, Diffuse

NCT06732401 2026-03-18

Testing the Addition of AZD6738 (Ceralasertib) to Immunotherapy to Increase Time Without Cancer for Patients With Non-Small Cell Lung Cancer

Phase 3 Suspended

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06802523 2026-03-18

Testing the Combination of Targeted Radiotherapy With Anti-Cancer Drugs, Venetoclax and ASTX-727, to Improve Outcomes for Adults With Newly Diagnosed Acute Myeloid Leukemia

Phase 1 Suspended

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT06888323 2026-03-18

Testing an Anti-cancer Radio-Active Immunotherapy Called Lintuzumab Ac225 in Patients With High-Risk Myelodysplastic Syndrome That Has Not Responded to Other Treatment

Phase 1 Suspended

Myelodysplastic Syndromes

NCT07283705 2026-03-18

A Phase II Study Evaluating BMS-986504 in MTAP-deleted Pancreatic Cancer

Phase 2 Suspended

Gastrointestinal

Phase 2 Study

NCT05111561 2026-03-17

Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast Cancer

Phase 1 Suspended

Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT05656131 2026-03-17

Fluzoparib in Combination With or Without Camrelizumab for Homologous Recombinant Deficiency (HRD) HER2 Negative Advanced Breast Cancer

Phase 2 Suspended

Advanced HER2 Negative Breast Carcinoma HRD+Breast Cancer

NCT07039630 2026-03-17

A Food Security Intervention for the Prevention of Cancer in Low-income Families

Phase NA Suspended

OtherOther neoplasm

Obesity-Related Malignant Neoplasm

NCT06626633 2026-03-12

2321GCCC: CRD3874-SI in Patients With Relapsed/Refractory AML

Phase 1 Suspended

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT07011550 2026-03-11

Phase 2, Single-arm Trial of BMS-986340 in Association With Nivolumab, Trifluridine/Tipiracil and Bevacizumab for Patients Refractory to Standard of Care Treatment and With Microsatellite-stable Colorectal Cancer

Phase 2 Suspended

Gastrointestinal

Microsatellite-stable Colorectal Cancer

NCT06963346 2026-03-09

Study Investigating Intravesical HDAC Inhibition to Improve Response to Immuno-Oncology Agents

Phase 1 Suspended

Urinary Bladder Neoplasms

NCT05597878 2026-03-06

Opioid-Free Pain Control Regimen Following Robotic Radical Prostatectomy

Phase 2/3 Suspended

Agnosia, Prostatic Neoplasms

NCT06219174 2026-03-06

Targeting ODC as an Immunotherapeutic Target in STK11 (LKB1) Pathway-Deficient NSCLC (DFMO)

Phase 1/2 Suspended

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06281925 2026-03-06

Cryotherapy & Oxaliplatin

Phase NA Suspended

Gastrointestinal

Colonic Neoplasms, Peripheral Nervous System Diseases

NCT06385262 2026-03-06

TOP 2301: Neoadjuvant Chemo for NSCLC

Phase 2 Suspended

Carcinoma, Non-Small-Cell Lung

NCT06860386 2026-03-06

Study of Adaptive Immunotherapy With VEGFR-TKI in Patients With Advanced RCC

Phase 2 Suspended

Carcinoma, Renal Cell

NCT03077841 2026-03-05

Hypofractionated Partial Breast Irradiation in Treating Patients With Early Stage Breast Cancer

Phase 2/3 Suspended

Breast Carcinoma In Situ, Breast Neoplasms, Carcinoma, Intraductal, Noninfiltrating

NCT06934928 2026-03-05

Assessing the Efficacy of Repeat, Monthly Treatments of Alexandrite Laser for NF1-associated Cutaneous Neurofibromas (cNFs)

Phase NA Suspended

Neurofibromatosis 1, Neurofibromatoses

NCT07136493 2026-03-05

Circulating Tumor DNA Based Minimal Residual Disease Detection for Patients With Early-Stage Breast Cancer

Phase NA Suspended

Triple Negative Breast Neoplasms

NCT03994796 2026-03-04

Genetic Testing in Guiding Treatment for Patients With Brain Metastases

Phase 2 Suspended

Brain Neoplasms, Neoplasm Metastasis

NCT05960773 2026-03-04

Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent, in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage Mesothelioma

Phase 2 Suspended

Other solid neoplasmThoracic

Mesothelioma, Malignant, Mesothelioma

NCT06159790 2026-03-04

A Study to Compare Efficacy, Safety, and Immunogenicity of GME751 and EU-authorized Keytruda in Adult Participants With Untreated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC)

Phase 3 Suspended

Carcinoma, Non-Small-Cell Lung

NCT06232044 2026-03-04

Testing the Combination of Two Approved Drugs and One Experimental Drug in Patients With Relapsed or Refractory Multiple Myeloma

Phase 1/2 Suspended

Multiple Myeloma

NCT06671912 2026-03-04

LoTam

Phase 3 Suspended

Breast Carcinoma In Situ

NCT05050162 2026-03-03

Comparing Cisplatin Every Three Weeks to Cisplatin Weekly When Combined With Radiation for Patients With Advanced Head and Neck Cancer

Phase 2/3 Suspended

Carcinoma, Oropharyngeal Neoplasms

NCT03150693 2026-03-02

Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia

Phase 3 Suspended

Burkitt Lymphoma

NCT06085729 2026-02-27

Phase I/II Study of PEGylated Arginine Deiminase (ADI-PEG20) With Carboplatin and Cabazitaxel in Men With Aggressive Variant Prostate Cancers (AVPC)

Phase 1/2 Suspended

Prostatic Neoplasms

NCT06235281 2026-02-27

PLIGHT

Phase EARLY_PHASE1 Suspended

Mycosis Fungoides

NCT05419479 2026-02-24

Switch Maintenance in Pancreatic

Phase 1/2 Suspended

Gastrointestinal

Pancreatic Neoplasms

NCT07025538 2026-02-23

Biomarker-Guided Ruxolitinib for the Prevention of Chronic Graft Versus Host Disease After Allogeneic Hematopoietic Cell Transplantation

Phase 1 Suspended

Hematopoietic and Lymphatic System Neoplasm

NCT07224503 2026-02-23

C-SMART vs BE Well for Patients With Brain Tumors

Phase NA Suspended

Brain Neoplasms

NCT05028621 2026-02-20

Molecular Basis of Langerhans and Non-Langerhans Cell Histiocytic Neoplasms and Castleman Disease

Phase NA Suspended

LymphoidMyeloid

Castleman Disease, Histiocytosis, Langerhans-Cell, Histiocytosis, Non-Langerhans-Cell

NCT02993068 2026-02-19

Stand up to Cancer: MAGENTA (Making Genetic Testing Accessible)

Phase NA Suspended

Triple Negative Breast Neoplasms

NCT05403723 2026-02-19

Adaptive SBRT Plus Chemoimmunotherapy for ES-SCLC

Phase 1 Suspended

Lung Neoplasms, Small Cell Lung Carcinoma

NCT06909201 2026-02-19

Hyperpolarized Xenon-129 Magnetic Resonance Imaging in Lung Cancer Patients Receiving Radiation Therapy for Investigating Radiation-response and Toxicity

Phase 1 Suspended

Lung Neoplasms

NCT05000294 2026-02-18

Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types

Phase 1/2 Suspended

BreastEndocrineGastrointestinalGenitourinaryGynecologicNETSarcoma

Bile Duct Neoplasms, Breast Neoplasms, Gallbladder Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Sarcoma, Vulvar Neoplasms, Carcinoma, Neuroendocrine, Neuroendocrine Tumors

NCT05378763 2026-02-18

PINNACLE

Phase 3 Suspended

NSCLC

NCT03467386 2026-02-17

Total Marrow and Lymphoid Irradiation Before Donor Transplant and Cyclophosphamide in Treating Patients With Acute Myeloid Leukemia

Phase 1 Suspended

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT06348147 2026-02-17

Dara-RVd Induction for Newly Diagnosed Multiple Myeloma With Autologous Stem Cell Transplantation

Phase 2 Suspended

Multiple Myeloma